- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: EVI1 Promotes the Proliferation and Invasive Properties of Human Head and Neck Squamous Cell Carcinoma Cells. (Pubmed Central) - Apr 9, 2022
So far, the EGFR inhibitor cetuximab is the only approved targeted therapy...Finally, EVI1 altered the expression of numerous genes in HNSCC cells, which were enriched for Gene Ontology terms related to its cellular functions. In summary, EVI1 represents a novel oncogene in HNSCC that contributes to cellular proliferation and invasiveness.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Nucleus Near-Infrared (nNIR) Irradiation of Single A549 Cells Induces DNA Damage and Activates EGFR Leading to Mitochondrial Fission. (Pubmed Central) - Apr 9, 2022
While the same phenomenon is also triggered by single molecular interactions between epidermal growth factor (EGF) and its receptor EGFR, pharmacological studies with cetuximab, PD153035, and caffeine suggest EGF signaling crosstalk to DNA damaging response to mediate rapid mitochondrial fission as a result of nNIR irradiation. These results suggest that nuclear DNA integrity is a novel biological target for cellular response to NIR.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, P1/2 data, Journal, PD(L)-1 Biomarker, IO biomarker: Phase Ib/II study of Cetuximab Plus Pembrolizumab in Patients with Advanced RAS wild-type Colorectal Cancer. (Pubmed Central) - Apr 8, 2022
The combination of cetuximab and pembrolizumab is inactive in patients with RASwt mCRC, despite its partial local immunologic efficacy. Further development of immuno-oncology combinations with enhanced efficacy and/or targeting additional or alternative immune checkpoints merits investigation.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD)
Journal, HEOR: Cost-effectiveness of Pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States. (Pubmed Central) - Apr 8, 2022
Pembrolizumab received FDA approval in 2020 for first-line treatment of Stage IV MSI-H/dMMR CRC based on significantly longer progression-free survival versus standard of care (SoC, 5-fluorouracil-based therapy with or without bevacizumab or cetuximab)...Pembrolizumab dominated FOLFOX + panitumumab, FOLFOXIRI, and FOLFOXIRI + bevacizumab, and presented ICERs of $35,220 and $276 against XELOX and XELOX + bevacizumab...Results were robust to sensitivity and scenario analyses. Pembrolizumab is highly cost-effective for the first-line treatment of unresectable or metastatic MSI-H/dMMR CRC in the US at a willingness-to-pay threshold of $100,000/QALY.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Small molecule profiling to define synergistic EGFR inhibitor combinations in head and neck squamous cell carcinoma. (Pubmed Central) - Apr 8, 2022
Pembrolizumab is highly cost-effective for the first-line treatment of unresectable or metastatic MSI-H/dMMR CRC in the US at a willingness-to-pay threshold of $100,000/QALY. Conceptually, our data identify novel synergistic combinations that warrant evaluation in future studies, and suggest that some combinations, although highly synergistic, will require parallel companion diagnostic development to be effectively advanced in patients.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Review, Journal: Hypomagnesemia in the Cancer Patient. (Pubmed Central) - Apr 8, 2022
We recommended checking serum magnesium at the beginning of treatment and as part of routine monitoring throughout cancer treatment. Opportunities exist for potential research and practice improvement, including further characterization of hypomagnesemia regarding the clinical effect on cancer outcomes, preventing hypomagnesemia in patients receiving high-risk anticancer agents, and developing effective therapeutic strategies.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Overcoming barriers to solid tumor immunotherapy using natural killer cell therapies designed to mimic intraepithelial group 1 innate lymphoid cells (Exhibit Hall; P978) - Apr 8, 2022 - Abstract #IMMUNOLOGY2022IMMUNOLOGY_1938;
We quantified the cytotoxicity of ieILC1-like cells against a variety of target cell lines and determined that they are broadly cytotoxic and capable of antibody-dependent cellular cytotoxicity, which was assessed using cetuximab...Preliminary in vivo work indicates that ieILC1-like cells perform comparably to K562-expanded NK cells. Thus, ieILC1-like NK cells represent a novel class of cell therapy that are more capable of infiltrating solid tumors and resisting their immunosuppressive cues.
- |||||||||| EGFR bi-armed autologous activated T cells / Barbara Ann Karmanos Cancer Institute
Trial completion, Enrollment change, Metastases: Anti-CD3 x Anti-Erbitux (clinicaltrials.gov) - Apr 7, 2022
P1, N=15, Completed,
Although the intervention met the need for support in recovery after treatment, it did not improve HRQoL or self-management skills. Active, not recruiting --> Completed | N=30 --> 15
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: EMT-mediated regulation of CXCL1/5 for resistance to anti-EGFR therapy in colorectal cancer. (Pubmed Central) - Apr 6, 2022
We further found that serum CXCL1/5 level was positively correlated with the presence of RAS/RAF mutation in colon cancer patients during cetuximab therapy, suggesting its role as a biomarker. These data indicated that the application of serum CXCL1/5 could be a potential serologic biomarker for predicting resistance to EGFR therapy in colorectal cancer.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Review, Journal, Heterogeneity: BRAF-mutated colorectal adenocarcinomas: pathological heterogeneity and clinical implications. (Pubmed Central) - Apr 6, 2022
Here, we discuss the heterogeneous pathologic and molecular landscape of BRAFmt CRCs, focusing on the promises and pitfalls of molecular diagnostics, on novel biomarkers to improve patients' stratification and on the current diagnostic scenario for CRC. We believe that a better stratification based on histopathological features and novel molecular biomarkers should be performed to optimize patient management and therapeutic decision-making.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Review, Journal, Combination therapy: Recent insights in the PI3K/Akt pathway as a promising therapeutic target in combination with EGFR-targeting agents to treat head and neck squamous cell carcinoma. (Pubmed Central) - Apr 5, 2022
Resistance to therapies targeting the epidermal growth factor receptor (EGFR), such as cetuximab, remains a major roadblock in the search for effective therapeutic strategies in head and neck squamous cell carcinoma (HNSCC)...Co-targeting EGFR and the PI3K/Akt pathway can lead to synergistic drug interactions, possibly restoring sensitivity to EGFR inhibitors and hereby improving clinical efficacy. Better understanding of the predictive value of PI3K/Akt pathway alterations is needed to allow the identification of patient populations that might benefit most from these combination strategies.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Senescence-associated reprogramming induced by interleukin-1 impairs response to EGFR neutralization. (Pubmed Central) - Apr 5, 2022
We identified that high miR-31 expression is associated with poor overall survival and progression-free survival and has a significant predictive value for anti-EGFR response. To sum up, our findings point to the combined blockage of IL-1R and EGFR as a promising therapeutical approach to restore sensitivity to EGFR-targeting monoclonal antibodies.
- |||||||||| Bavencio (avelumab) / EMD Serono, Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / Ono Pharma, BMS
Journal, PD(L)-1 Biomarker, IO biomarker: Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial. (Pubmed Central) - Apr 5, 2022
To sum up, our findings point to the combined blockage of IL-1R and EGFR as a promising therapeutical approach to restore sensitivity to EGFR-targeting monoclonal antibodies. DDR mutations may contribute to DDR-induced STING pathway with sustained innate immunity activation following cetuximab plus avelumab combination in previously treated, PD-1 inhibitor responsive NSCLC patients.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal, Tumor Mutational Burden, PD(L)-1 Biomarker, IO biomarker: Advances in targeted therapy for anaplastic thyroid carcinoma. (Pubmed Central) - Apr 5, 2022
The mammalian target of rapamycin pathway inhibitors, peroxisome proliferators-activated receptor γ agonists, endothelial growth factor receptors-targeting monoclonal antibody cetuximab and novel vascular blocker fosbretabulin are still in the clinical research stage, which are expected to provide new directions for the development of novel targeted drugs. This article reviews the current research progress on targeted drugs for the treatment of ATC.
- |||||||||| Hensify (crystalline hafnium oxide) / Nanobiotix, J&J
Enrollment open, Trial initiation date, Trial primary completion date, Combination therapy: NANORAY-312: NBTXR3 With or Without Cetuximab in LA-HNSCC (clinicaltrials.gov) - Apr 4, 2022
P3, N=500, Recruiting,
Recruiting --> Completed Not yet recruiting --> Recruiting | Initiation date: Jul 2021 --> Jan 2022 | Trial primary completion date: Dec 2023 --> Jul 2024
- |||||||||| Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Metastatic colorectal cancer in both sides of Aegean Sea: practice patterns and outcome. (Pubmed Central) - Apr 2, 2022
As first-line therapy, 196 (54%) patients received bevacizumab and Anti-EGFR treatments in combination with chemotherapy...In conclusion, it seems that the patient's performance status, tumor location, number of metastatic lesions at the time of diagnosis affect the prognosis of mCRC. Although access to molecular tests and first-line treatments differ between Greece and Turkey, no significant difference was found in survival times.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Reducing skin toxicities from EGFR inhibitors with topical BRAF inhibitor therapy. (Pubmed Central) - Apr 1, 2022
The acneiform rash improved in the six patients who started with grade 2 rash in the low and intermediate cohorts. We conclude that topical LUT014 is safe and efficacious in improving rash from EGFR inhibitors, consistent with the mechanism of action inducting paradoxical MAPK activation.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Review, Journal: The dogma of Cetuximab and Radiotherapy in head and neck cancer - A dawn to dusk journey. (Pubmed Central) - Apr 1, 2022
After the initial success, Cetuximab has miserably failed to win over cisplatin based chemoradiation which is the current standard of care in LA-HNSCC. Hence, it is the need of the hour to re-evaluate and define the present role of Cetuximab in the definitive management of LA-HNSCC in the light of the latest clinical evidence..
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche, Nerlynx (neratinib) / Puma
Enrollment closed, Trial completion date, Metastases: NSABP FC-11: Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status (clinicaltrials.gov) - Mar 31, 2022
P2, N=35, Active, not recruiting,
Hence, it is the need of the hour to re-evaluate and define the present role of Cetuximab in the definitive management of LA-HNSCC in the light of the latest clinical evidence.. Recruiting --> Active, not recruiting | Trial completion date: Jan 2022 --> Sep 2022
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Preclinical, Journal: Comprehensive Molecular Landscape of Cetuximab Resistance in Head and Neck Cancer Cell Lines. (Pubmed Central) - Mar 31, 2022
Overall, we identified several molecular alterations in the cetuximab resistant cell line that may constitute novel biomarkers of cetuximab response such as mTOR and RhoA overexpression. These findings indicate new strategies to overcome anti-EGFR resistance in HNSCC.
- |||||||||| Trial completion date, Trial primary completion date, Metastases: QUILT-3.071: QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine (clinicaltrials.gov) - Mar 29, 2022
P1b/2, N=332, Active, not recruiting,
The DIRECT study showed that first-line cetuximab plus PBT was a feasible, beneficial first-line treatment regimen in patients with R/M SCCHN in the real-world setting. Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022
|
